Metabolic memory phenomenon in diabetes mellitus: Achieving and perspectives

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 10, Issue 2, 2016, Pages S176-S183

  Berezin, Alexander ^a  

^a ZAPORIZHZHIA STATE MEDICAL UNIVERSITY   (Ukraine)

Author keywords

Diabetes mellitus; Epigenetic modulation; Inflammation; Metabolic memory phenomenon; Oxidative stress

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FIBRIC ACID DERIVATIVE; GLUCOSE; INCRETIN; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER; SULFONYLUREA DERIVATIVE;

DIABETES MELLITUS; EPIGENETICS; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INFLAMMATION; METABOLIC REGULATION; MONONUCLEAR CELL; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STEM CELL; VASCULAR DISEASE; ANTAGONISTS AND INHIBITORS; DIABETES COMPLICATIONS; GENETIC EPIGENESIS; GENETICS; METABOLISM; PHYSIOLOGY;

DIABETES COMPLICATIONS; DIABETES MELLITUS; EPIGENESIS, GENETIC; FIBRIC ACIDS; HUMANS; INCRETINS; INSULIN; METFORMIN; OXIDATIVE STRESS; SODIUM-GLUCOSE TRANSPORT PROTEINS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 85027955699     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2016.03.016     Document Type: Review

References (102)

1. Engelgau, M.M., Geiss, L.S., Saaddine, J.B., Boyle, J.P., Benjamin, S.M., Gregg, E.W., et al. The evolving diabetes burden in the United States. Ann Intern Med 140:11 (2004), 945–950.
2. Saadi, H., Carruthers, S.G., Nagelkerke, N., Al-Maskari, F., Afandi, B., Reed, R., et al. Prevalence of diabetes mellitus and its complications in a population-based sample in Al Ain, United Arab Emirates. Diabetes Res Clin Pract 78:3 (2007), 369–377.
3. Deshpande, A., Harris-Hayes, M., Schootman, M., Epidemiology of diabetes and diabetes-related complications. Phys Ther 88 (2008), 1254–1264.
4. Dall, T.M., Storm, M.V., Semilla, A.P., Wintfeld, N., O'Grady, M., Narayan, K.M., Value of lifestyle intervention to prevent diabetes and sequelae. Am J Prev Med 48:3 (2015), 271–280.
5. Williamson, C., Glauser, T.A., Burton, B.S., Schneider, D., Dubois, A.M., Patel, D., Health care provider management of patients with type 2 diabetes mellitus: analysis of trends in attitudes and practices. Postgrad Med 126:3 (2014), 145–160.
6. Dall, T.M., Narayan, K.M., Gillespie, K.B., Gallo, P.D., Blanchard, T.D., Solcan, M., et al. Detecting type 2 diabetes and prediabetes among asymptomatic adults in the United States: modeling American Diabetes Association versus US Preventive Services Task Force diabetes screening guidelines. Popul Health Metr, 12, 2014, 12.
7. Smith, J., Nazare, J.A., Borel, A.L., Aschner, P., Barter, P.J., Van Gaal, L., et al. Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from INSPIRE ME IAA. Diabetes Obes Metab 15:7 (2013), 629–641.
8. Greenfield, S., Billimek, J., Pellegrini, F., Franciosi, M., De Berardis, G., Nicolucci, A., et al. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med 151 (2009), 854–860.
9. Tuttle, K.R., Bakris, G.L., Bilous, R.W., Chiang, J.L., de Boer, I.H., Goldstein-Fuchs, J., et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis 64:4 (2014), 510–533.
10. Lloyd, A., Perspectives on diabetic retinopathy. Am J Ophthalmol 136 (2003), 122–135.
11. Bjornstad, P., Pyle, L., Nguyen, N., Snell-Bergeon, J.K., Bishop, F.K., Wadwa, R.P., et al. Achieving International Society for Pediatric and Adolescent Diabetes and American Diabetes Association clinical guidelines offers cardiorenal protection for youth with type 1 diabetes. Pediatr Diabetes 16:1 (2015), 22–30.
12. Insuchi, S., Bergenstal, R., Buse, J., Diamant, M., Ferrannini, E., Nauck, M., Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care 35 (2012), 1364–1379.
13. Matthews, D.R., Tsapas, A., Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. Diabetes Vasc Dis Res 5 (2008), 216–218.
14. Comaschi, M., Coscelli, C., Cucinotta, D., Malini, P., Manzato, E., Nicolucci, A., Cardiovascular risk factors and metabolic control in type 2 diabetic subjects attending outpatient clinics in Italy: the SFIDA (survey of risk factors in Italian diabetic subjects by AMD) study. Nutr Metab Cardiovasc Dis 15:3 (2005), 204–211.
15. Regensteiner, J.G., Golden, S., Huebschmann, A.G., Barrett-Connor, E., Chang, A.Y., Chyun, D., et al. Sex differences in the cardiovascular consequences of diabetes mellitus: a scientific statement from the American Heart Association. Circulation 132:25 (2015), 2424–2447.
16. Fox, C.S., Golden, S.H., Anderson, C., Bray, G.A., Burke, L.E., de Boer, I.H., et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 38:9 (2015), 1777–1803.
17. Skyler, J.S., Bergenstal, R., Bonow, R.O., Buse, J., Deedwania, P., Gale, E.A., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32 (2009), 187–192.
18. Brown, A., Reynolds, L.R., Bruemmer, D., Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 7:7 (2010), 369–375.
19. Turner, R.C., Holman, R.R., Cull, C.A., UK Prospective Diabetes Study (UKPDS) Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865.
20. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
21. Gerstein, H.C., Miller, M.E., Byington, R.P., Goff, D.C. Jr., Bigger, J.T., Buse, J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
22. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
23. Riddle, M.C., Counterpoint: intensive glucose control and mortality in ACCORD – still looking for clues. Diabetes Care 33 (2010), 2722–2724.
24. Paneni, F., Beckman, J.A., Creager, M.A., Cosentino, F., Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Eur Heart J 34 (2013), 2436–2443.
25. Ceriello, A., The emerging challenge in diabetes: the “metabolic memory”. Vasc Pharmacol 57 (2012), 133–138.
26. Ceriello, A., Ihnat, M.A., Thorpe, J.E., Clinical review 2: the “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications?. J Clin Endocrinol Metab 94 (2009), 410–415.
27. Ihnat, M.A., Thorpe, J.E., Ceriello, A., Hypothesis: the ‘metabolic memory’, the new challenge of diabetes. Diabet Med 24:6 (2007), 582–586.
28. Costantino, S., Paneni, F., Cosentino, F., Hyperglycemia: a bad signature on the vascular system. Cardiovasc Diagn Ther 5:5 (2015), 403–406.
29. Bianchi, C., Miccoli, R., Del Prato, S., Hyperglycemia and vascular metabolic memory: truth or fiction?. Curr Diabetes Rep 13:3 (2013), 403–410.
30. Genuth, S., Sun, W., Cleary, P., Gao, X., Sell, D.R., Lachin, J., et al. Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Diabetes 64:1 (2015), 266–278.
31. Pacher, P., Szabó, C., Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol 6:2 (2006), 136–141.
32. Lupachyk, S., Shevalye, H., Maksimchyk, Y., Drel, V.R., Obrosova, I.G., PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function. Free Radic Biol Med 50:10 (2011), 1400–1409.
33. Sarras, M.P. Jr., Leontovich, A.A., Intine, R.V., Use of zebrafish as a model to investigate the role of epigenetics in propagating the secondary complications observed in diabetes mellitus. Comp Biochem Physiol C: Toxicol Pharmacol 178 (2015), 3–7.
34. Santos, J.M., Mishra, M., Kowluru, R.A., Posttranslational modification of mitochondrial transcription factor A in impaired mitochondria biogenesis: implications in diabetic retinopathy and metabolic memory phenomenon. Exp Eye Res 121 (2014), 168–177.
35. Kowluru, R.A., Mitochondria damage in the pathogenesis of diabetic retinopathy and in the metabolic memory associated with its continued progression. Curr Med Chem 20:26 (2013), 3226–3233.
36. Zhong, X., Liao, Y., Chen, L., Liu, G., Feng, Y., Zeng, T., et al. The MicroRNAs in the pathogenesis of metabolic memory. Endocrinology 156:9 (2015), 3157–3168.
37. Zhao, S., Li, T., Li, J., Lu, Q., Han, C., Wang, N., et al. miR-23b-3p induces the cellular metabolic memory of high glucose in diabetic retinopathy through a SIRT1-dependent signalling pathway. Diabetologia 59:3 (2016), 644–654.
38. Prattichizzo, F., Giuliani, A., Ceka, A., Rippo, M.R., Bonfigli, A.R., Testa, R., et al. Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes. Clin Epigenetics, 7(1), 2015, 56.
39. Piperi, C., Goumenos, A., Adamopoulos, C., Papavassiliou, A.G., AGE/RAGE signaling regulation by miRNAs: associations with diabetic complications and therapeutic potential. Int J Biochem Cell Biol 60 (2015), 197–201.
40. Wegner, M., Neddermann, D., Piorunska-Stolzmann, M., Jagodzinski, P.P., Role of epigenetic mechanisms in the development of chronic complications of diabetes. Diabetes Res Clin Pract 105:2 (2014), 164–175.
41. Rajasekar, P., O'Neill, C.L., Eeles, L., Stitt, A.W., Medina, R.J., Epigenetic changes in endothelial progenitors as a possible cellular basis for glycemic memory in diabetic vascular complications. J Diabetes Res, 2015, 2015, 436879.
42. Costantino, S., Paneni, F., Cosentino, F., Targeting chromatin remodeling to prevent cardiovascular disease in diabetes. Curr Pharm Biotechnol 16:6 (2015), 531–543.
43. Mishra, M., Zhong, Q., Kowluru, R.A., Epigenetic modifications of Keap1 regulate its interaction with the protective factor Nrf2 in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 55:11 (2014), 7256–7265.
44. Reddy, M.A., Zhang, E., Natarajan, R., Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia 58:3 (2015), 443–455.
45. Mishra, M., Zhong, Q., Kowluru, R.A., Epigenetic modifications of Nrf2-mediated glutamate-cysteine ligase: implications for the development of diabetic retinopathy and the metabolic memory phenomenon associated with its continued progression. Free Radic Biol Med 75 (2014), 129–139.
46. Ling, C., Del Guerra, S., Lupi, R., Rönn, T., Granhall, C., Luthman, H., et al. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 51:4 (2008), 615–622.
47. Zhao, J., Goldberg, J., Bremner, J.D., Vaccarino, V., Global, D.N.A., methylation is associated with insulin resistance: a monozygotic twin study. Diabetes 61 (2012), 542–546.
48. Sapienza, C., Lee, J., Powell, J., Erinle, O., Yafai, F., Reichert, J., et al. DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics 6 (2011), 20–28.
49. Rakyan, V.K., Beyan, H., Down, T.A., Hawa, M.I., Maslau, S., Aden, D., et al. Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet, 7, 2011, e1002300.
50. Akirav, E.M., Lebastchi, J., Galvan, E.M., Henegariu, O., Akirav, M., Ablamunits, V., et al. Detection of β cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci U S A 108 (2011), 19018–19023.
51. Volkmar, M., Dedeurwaerder, S., Cunha, D.A., Ndlovu, M.N., Defrance, M., Deplus, R., et al. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. EMBO J 31 (2012), 1405–1426.
52. Dayeh, T., Volkov, P., Salö, S., Hall, E., Nilsson, E., Olsson, A.H., et al. Genome-wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion. PLoS Genet, 10(3), 2014, e1004160.
53. Rönn, T., Ling, C., DNA methylation as a diagnostic and therapeutic target in the battle against type 2 diabetes. Epigenomics 7:3 (2015), 451–460.
54. Infante-Garcia, C., Ramos-Rodriguez, J.J., Galindo-Gonzalez, L., Garcia-Alloza, M., Long-term central pathology and cognitive impairment are exacerbated in a mixed model of Alzheimer's disease and type 2 diabetes. Psychoneuroendocrinology 65 (2015), 15–25.
55. Chentli, F., Azzoug, S., Mahgoun, S., Diabetes mellitus in elderly. Indian J Endocrinol Metab 19:6 (2015), 744–752.
56. Thomas, M.C., Glycemic exposure, glycemic control, and metabolic karma in diabetic complications. Adv Chronic Kidney Dis 21:3 (2014), 311–317.
57. Lachin, J.M., White, N.H., Hainsworth, D.P., Sun, W., Cleary, P.A., Nathan, D.M., Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes 64:2 (2015), 631–642.
58. Cameron, F.J., Baghurst, P.A., Rodbard, D., Assessing glycemic variation: why, when and how?. Pediatr Endocrinol Rev 7:Suppl. 3 (2010), 432–444.
59. Chen, F., Dong, R.R., Zhong, K.L., Ghosh, A., Tang, S.S., Long, Y., et al. Antidiabetic drugs restore abnormal transport of amyloid-β across the blood-brain barrier and memory impairment in db/db mice. Neuropharmacology 101 (2016), 123–136.
60. Vinik, A., Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther, 29, 2007 Spec No: 1236–53.
61. Fullerton, B., Jeitler, K., Seitz, M., Horvath, K., Berghold, A., Siebenhofer, A., Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev, 2, 2014 CD009122.
62. Danne, T., von Schütz, W., Lange, K., Nestoris, C., Datz, N., Kordonouri, O., Current practice of insulin pump therapy in children and adolescents – the Hannover recipe. Pediatr Diabetes 7:Suppl. 4 (2006), 25–31.
63. Zheng, Z., Chen, H., Li, J., Li, T., Zheng, B., Zheng, Y., et al. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes 61:1 (2012), 217–228.
64. Zhang, E., Guo, Q., Gao, H., Xu, R., Teng, S., Wu, Y., Metformin and resveratrol inhibited high glucose-induced metabolic memory of endothelial senescence through SIRT1/p300/p53/p21 pathway. PLOS ONE, 10(12), 2015, e0143814.
65. Potter, W.B., O'Riordan, K.J., Barnett, D., Osting, S.M., Wagoner, M., Burger, C., et al. Metabolic regulation of neuronal plasticity by the energy sensor AMPK. PLoS ONE, 5(2), 2010 e8996.
66. Patrone, C., Eriksson, O., Lindholm, D., Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes Endocrinol 2:3 (2014), 256–262.
67. Allard, J.S., Perez, E.J., Fukui, K., Carpenter, P., Ingram, D.K., Cabo, R., Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice. Behav Brain Res 301 (2015), 1–9.
68. Pintana, H., Apaijai, N., Pratchayasakul, W., Chattipakorn, N., Chattipakorn, S.C., Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci 91:11–12 (2012), 409–414.
69. Davidson, J.A., Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clin Proc 85:Suppl. 12 (2010), S27–S37.
70. DeFronzo, R.A., Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med 123:Suppl. 3 (2010), S38–S48.
71. Nauck, M.A., Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 124:Suppl. 1 (2011), S3–S18.
72. Dai, Y., Dai, D., Wang, X., Ding, Z., Mehta, J.L., DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway. Cardiovasc Drugs Ther 28:5 (2014), 425–432.
73. Horie, A., Tokuyama, Y., Ishizuka, T., Suzuki, Y., Marumo, K., Oshikiri, K., et al. The dipeptidyl peptidase-4 inhibitor vildagliptin has the capacity to repair β-cell dysfunction and insulin resistance. Horm Metab Res 46:11 (2014), 814–818.
74. Katagiri D1, Hamasaki, Y., Doi, K., Okamoto, K., Negishi, K., Nangaku, M., et al. Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. J Am Soc Nephrol 24:12 (2013), 2034–2043.
75. Ishibashi, Y., Matsui, T., Maeda, S., Higashimoto, Y., Yamagishi, S., Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol, 12, 2013, 125.
76. Nakashima, S., Matsui, T., Takeuchi, M., Yamagishi, S.I., Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res 46:10 (2014), 717–721.
77. 2 treatment enhances engraftment of mouse bone marrow hematopoietic stem cells. Blood Cells Mol Dis 53:1–2 (2014), 34–38.
78. Liu, L., Liu, J., Tian, X.Y., Wong, W.T., Lau, C.W., Xu, A., et al. Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress. Antioxid Redox Signal 21:11 (2014), 1571–1581.
79. Aso, Y., Jojima, T., Iijima, T., Suzuki, K., Terasawa, T., Fukushima, M., et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34(+)CXCR4(+) cells in patients with type 2 diabetes. Endocrine 50:3 (2015), 659–664.
80. Ojima, A., Matsui, T., Maeda, S., Takeuchi, M., Yamagishi, S., Glucose-dependent insulinotropic polypeptide (GIP) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its antioxidative properties. Horm Metab Res 44:7 (2012), 501–505.
81. Ishibashi, Y., Matsui, T., Takeuchi, M., Yamagishi, S., Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm Metab Res 43:10 (2011), 731–734.
82. Mizuno, C.S., Chittiboyina, A.G., Kurtz, T.W., Pershadsingh, H.A., Avery, M.A., Type 2 diabetes and oral antihyperglycemic drugs. Curr Med Chem 15 (2008), 61–74.
83. Sliwinska, A., Rogalska, A., Szwed, M., Kasznicki, J., Jozwiak, Z., Drzewoski, J., Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells. Mol Biol Rep 39:5 (2012), 5253–5267.
84. Ma, L., Lu, N., Wu, G., Antiplatelet aggregation and endothelial protection of I4, a new synthetic anti-diabetes sulfonylurea compound. Platelets 26:4 (2015), 342–348.
85. Avogaro, A., Treating diabetes today with gliclazide MR: a matter of numbers. Diabetes Obes Metab 14:Suppl. 1 (2012), 14–19.
86. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:24 (2008), 2560–2572.
87. Montori, V.M., Malaga, G., Intensive glucose control did not prevent important complications in type 2 diabetes. Evid Based Med 13:6 (2008), 168–169.
88. Mattila, T.K., de Boer, A., Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. Drugs 70:17 (2010), 2229–2245.
89. Hemmingsen, B., Lund, S.S., Gluud, C., Vaag, A., Almdal, T.P., Hemmingsen, C., et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev, 11, 2013, CD008143.
90. Mughal, A., Kumar, D., Vikram, A., Effects of Thiazolidinediones on metabolism and cancer: relative influence of PPARγ and IGF-1 signaling. Eur J Pharmacol 768 (2015), 217–225.
91. Martins, F.O., Delgado, T.C., Viegas, J., Gaspar, J., Scott, D.K., O'Doherty, R.M., et al. Mechanisms by which the thiazolidinedione troglitazone protects against sucrose-induced hepatic fat accumulation and hyperinsulinemia. Br J Pharmacol, 2015, 10.1111/bph.13362 [Epub ahead of print].
92. Nathan, D.M., Diabetes: advances in diagnosis and treatment. J Am Med Assoc 314:10 (2015), 1052–1062.
93. Lozano-Ortega, G., Goring, S., Bennett, H.A., Bergenheim, K., Sternhufvud, C., Mukherjee, J., Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin + sulfonylurea. Curr Med Res Opin, 2015, 1–44 [Epub ahead of print].
94. Katz, P.M., Leiter, L.A., The role of the kidney and SGLT2 inhibitors in type 2 diabetes. Can J Diabetes 39:Suppl. 5 (2015), S167–S175.
95. Neeland, I.J., Salahuddin, U., McGuire, D.K., A safety evaluation of empagliflozin for the treatment of type 2 diabetes. Expert Opin Drug Saf 15:3 (2016), 393–402.
96. Bode, B.W., Garg, S.K., The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes. Endocr Pract 22:2 (2016), 220–230.
97. Shimo, N., Matsuoka, T.A., Miyatsuka, T., Takebe, S., Tochino, Y., Takahara, M., et al. Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key β-cell factors under diabetic conditions. Biochem Biophys Res Commun 467:4 (2015), 948–954.
98. Franceschini, G., Favari, E., Calabresi, L., Simonelli, S., Bondioli, A., Adorni, M.P., et al. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. J Clin Lipidol 7:5 (2013), 414–422.
99. Alrasadi, K., Awan, Z., Alwaili, K., Ruel, I., Hafiane, A., Krimbou, L., et al. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g). Am J Cardiol 102:10 (2008), 1341–1347.
100. Sorrentino, S.A., Besler, C., Rohrer, L., Meyer, M., Heinrich, K., Bahlmann, F.H., et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 121:1 (2010), 110–122.
101. Kuvin, J.T., Rämet, M.E., Patel, A.R., Pandian, N.G., Mendelsohn, M.E., Karas, R.H., A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 144:1 (2002), 165–172.
102. Zhao, S., Li, J., Wang, N., Zheng, B., Li, T., Gu, Q., et al. Fenofibrate suppresses cellular metabolic memory of high glucose in diabetic retinopathy via a sirtuin 1-dependent signalling pathway. Mol Med Rep 12:4 (2015), 6112–6118.